These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 10837943)

  • 41. High-dose radiotherapy with or without androgen deprivation therapy for intermediate-risk prostate cancer: cancer control and toxicity outcomes.
    Edelman S; Liauw SL; Rossi PJ; Cooper S; Jani AB
    Int J Radiat Oncol Biol Phys; 2012 Aug; 83(5):1473-9. PubMed ID: 22245201
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Improved biochemical disease-free survival of men younger than 60 years with prostate cancer treated with high dose conformal external beam radiotherapy.
    Zelefsky MJ; Marion C; Fuks Z; Leibel SA
    J Urol; 2003 Nov; 170(5):1828-32. PubMed ID: 14532785
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Survival Outcomes of Whole-Pelvic Versus Prostate-Only Radiation Therapy for High-Risk Prostate Cancer Patients With Use of the National Cancer Data Base.
    Amini A; Jones BL; Yeh N; Rusthoven CG; Armstrong H; Kavanagh BD
    Int J Radiat Oncol Biol Phys; 2015 Dec; 93(5):1052-63. PubMed ID: 26581142
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The need for more aggressive therapy for men with Gleason 9-10 disease compared to Gleason ≤8 high-risk prostate cancer.
    Safdieh JJ; Schwartz D; Weiner JP; Nwokedi E; Schreiber D
    Tumori; 2016; 102(2):168-73. PubMed ID: 26917408
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Correlation of clinical and pathologic factors with rising prostate-specific antigen profiles after radical prostatectomy alone for clinically localized prostate cancer.
    Kupelian P; Katcher J; Levin H; Zippe C; Klein E
    Urology; 1996 Aug; 48(2):249-60. PubMed ID: 8753737
    [TBL] [Abstract][Full Text] [Related]  

  • 46. New Prostate Cancer Grading System Predicts Long-term Survival Following Surgery for Gleason Score 8-10 Prostate Cancer.
    Ham WS; Chalfin HJ; Feng Z; Trock BJ; Epstein JI; Cheung C; Humphreys E; Partin AW; Han M
    Eur Urol; 2017 Jun; 71(6):907-912. PubMed ID: 27876305
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Interim report of image-guided conformal high-dose-rate brachytherapy for patients with unfavorable prostate cancer: the William Beaumont phase II dose-escalating trial.
    Martinez AA; Kestin LL; Stromberg JS; Gonzalez JA; Wallace M; Gustafson GS; Edmundson GK; Spencer W; Vicini FA
    Int J Radiat Oncol Biol Phys; 2000 May; 47(2):343-52. PubMed ID: 10802358
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Relationship between percent positive biopsies and biochemical outcome after permanent interstitial brachytherapy for clinically organ-confined carcinoma of the prostate gland.
    Merrick GS; Butler WM; Galbreath RW; Lief JH; Adamovich E
    Int J Radiat Oncol Biol Phys; 2002 Mar; 52(3):664-73. PubMed ID: 11849788
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Impact of biochemical failure on overall survival after radiation therapy for localized prostate cancer in the PSA era.
    Kupelian PA; Buchsbaum JC; Patel C; Elshaikh M; Reddy CA; Zippe C; Klein EA
    Int J Radiat Oncol Biol Phys; 2002 Mar; 52(3):704-11. PubMed ID: 11849793
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Five-year biochemical outcome and toxicity with transperineal CT-planned permanent I-125 prostate implantation for patients with localized prostate cancer.
    Zelefsky MJ; Hollister T; Raben A; Matthews S; Wallner KE
    Int J Radiat Oncol Biol Phys; 2000 Jul; 47(5):1261-6. PubMed ID: 10889379
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Predictors of metastatic disease after prostate brachytherapy.
    Forsythe K; Burri R; Stone N; Stock RG
    Int J Radiat Oncol Biol Phys; 2012 Jun; 83(2):645-52. PubMed ID: 22137025
    [TBL] [Abstract][Full Text] [Related]  

  • 52. External beam radiotherapy for clinically node-negative, localized hormone-refractory prostate cancer: impact of pretreatment PSA value on radiotherapeutic outcomes.
    Akimoto T; Kitamoto Y; Saito J; Harashima K; Nakano T; Ito K; Yamamoto T; Kurokawa K; Yamanaka H; Takahashi M; Mitsuhashi N; Niibe H
    Int J Radiat Oncol Biol Phys; 2004 Jun; 59(2):372-9. PubMed ID: 15145150
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Lymph node-positive prostate cancer: evaluation of the results of the combination of androgen deprivation therapy and radiation therapy.
    Buskirk SJ; Pisansky TM; Atkinson EJ; Schild SE; O'Brien PC; Wolfe JT; Zincke H
    Mayo Clin Proc; 2001 Jul; 76(7):702-6. PubMed ID: 11444402
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The prognostic significance of Gleason scores in metastatic prostate cancer.
    Rusthoven CG; Carlson JA; Waxweiler TV; Yeh N; Raben D; Flaig TW; Kavanagh BD
    Urol Oncol; 2014 Jul; 32(5):707-13. PubMed ID: 24629494
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Preliminary report of toxicity following 3D radiation therapy for prostate cancer on 3DOG/RTOG 9406.
    Michalski JM; Purdy JA; Winter K; Roach M; Vijayakumar S; Sandler HM; Markoe AM; Ritter MA; Russell KJ; Sailer S; Harms WB; Perez CA; Wilder RB; Hanks GE; Cox JD
    Int J Radiat Oncol Biol Phys; 2000 Jan; 46(2):391-402. PubMed ID: 10661346
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Localized prostate cancer treated by external-beam radiotherapy alone: serum prostate-specific antigen--driven outcome analysis.
    Lee WR; Hanks GE; Schultheiss TE; Corn BW; Hunt MA
    J Clin Oncol; 1995 Feb; 13(2):464-9. PubMed ID: 7531222
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Long-term outcome after elective irradiation of the pelvic lymphatics and local dose escalation using high-dose-rate brachytherapy for locally advanced prostate cancer.
    Galalae RM; Kovács G; Schultze J; Loch T; Rzehak P; Wilhelm R; Bertermann H; Buschbeck B; Kohr P; Kimmig B
    Int J Radiat Oncol Biol Phys; 2002 Jan; 52(1):81-90. PubMed ID: 11777625
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Cardiovascular Mortality Following Short-term Androgen Deprivation in Clinically Localized Prostate Cancer: An Analysis of RTOG 94-08.
    Voog JC; Paulus R; Shipley WU; Smith MR; McGowan DG; Jones CU; Bahary JP; Zeitzer KL; Souhami L; Leibenhaut MH; Rotman M; Husain SM; Gore E; Raben A; Chafe S; Sandler HM; Efstathiou JA
    Eur Urol; 2016 Feb; 69(2):204-10. PubMed ID: 26362090
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Pretreatment prostate-specific antigen and Gleason score predict the risk of extracapsular extension and the risk of failure following radiotherapy in patients with clinically localized prostate cancer.
    Roach M; Chen A; Song J; Diaz A; Presti J; Carroll P
    Semin Urol Oncol; 2000 May; 18(2):108-14. PubMed ID: 10875450
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Long-term results of an RTOG Phase II trial (00-19) of external-beam radiation therapy combined with permanent source brachytherapy for intermediate-risk clinically localized adenocarcinoma of the prostate.
    Lawton CA; Yan Y; Lee WR; Gillin M; Firat S; Baikadi M; Crook J; Kuettel M; Morton G; Sandler H
    Int J Radiat Oncol Biol Phys; 2012 Apr; 82(5):e795-801. PubMed ID: 22330999
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.